Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03474718
Other study ID # IRB00045844
Secondary ID
Status Not yet recruiting
Phase Early Phase 1
First received
Last updated
Start date August 2024
Est. completion date December 2024

Study information

Verified date May 2024
Source Wake Forest University Health Sciences
Contact Research Coordinator
Phone 336-716-2903
Email irichard@wakehealth.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study team will assess the efficacy of platelet-rich plasma therapy, a special blood product which is from the participant's own body, in the treatment of androgenic alopecia (also known as male pattern hair loss) in females.


Description:

Androgenic alopecia, or male-pattern hair loss affects both men and women. This hair loss pattern is typically characterized by thinning at the crown of scalp and/or M-shaped hair line in males or diffuse thinning throughout in females. Platelet-rich plasma (PRP) therapy has recently been studied as a hair rejuvenation therapy in patients with non-inflammatory alopecia. Though the mechanism of action is not well understood, PRP is thought to promote angiogenesis and enhance blood flow around hair follicles via platelet-derived growth factor (PDGF), transforming growth factor (TGF), and vascular endothelial growth factor (VEGF). The primary objective of the study is to determine whether PRP, administered once monthly for 3 months improves clinical outcomes and quality of life in females with androgenic alopecia. This is a randomized, placebo-controlled, double-blind, half-head, single center clinical study where sixteen subjects with androgenic alopecia will be recruited. Dermatology Life Quality Index will be assessed at several time points. Disease severity will be measured using the Severity of Alopecia Tool (SALT), Alopecia Density and Extent Score (ALODEX); Trichoscan images will be captured to document participants' clinical progress. Adverse events will be recorded at each visit, treatment will be discontinued if any subject experience a serious adverse event. Treatment visits will take place at baseline, 4 weeks (1 month), 8 weeks (2 months), and 12 weeks (3 month). A follow-up, non-treatment visit will take place at 24 weeks (6 months). The study team hypothesizes that PRP will improve DLQI, SALT, ALODEX, hair count (number of hairs/0.65 cm2), hair density (number of hairs/cm2), hair diameter, anagen to telogen ratio, and vellus hair to terminal hair ratio in female subjects with androgenic alopecia.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 16
Est. completion date December 2024
Est. primary completion date November 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Female =18 years of age at baseline visit. - Documentation of androgenic alopecia diagnosis as evidenced by one or more clinical features - Not currently on any treatment for alopecia, or has undergone 2-week washout period if recently on medication(s) for alopecia - Written informed consent obtained from subject and ability for subject to comply with the requirements of the study Exclusion Criteria: - Pregnant or breastfeeding - Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data. - Have an infection, metastatic disease or certain skin conditions (ie. Psoriasis) which could worsen or spread with injections - Diagnosed with a blood or bleeding disorder - Diagnosed with anemia - Currently on anticoagulant therapy

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Platelet-rich Plasma Left Side
Group A will receive PRP on left side of scalp and placebo (saline solution) on right side of scalp.
Platelet-rich Plasma Right Side
Group B will receive PRP on right side of scalp and placebo (saline solution) on left side of scalp.

Locations

Country Name City State
United States Wake Forest University Baptist Health Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Wake Forest University Health Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in Hair Diameter Change in Hair Diameter, as assessed via Trichoscan 6 months
Other Anagen to Telogen Ratio Anagen to Telogen Ratio, as assessed via Trichoscan 6 months
Other Vellus Hair to Terminal Hair Ratio Vellus Hair to Terminal Hair Ratio, as assessed via Trichoscan 6 months
Other Change in Dermatology Life Quality Index (DLQI) Change in Dermatology Life Quality Index (DLQI)
10 question are asked pertaining to symptoms and feelings, daily activities, leisure, work and school, personal relationships and treatment.
The scoring of each answer is as follows:
Very much scored 3 A lot scored 2 A little scored 1 Not at all scored 0 Not relevant scored 0 Question unanswered scored 0 Question 7: "prevented work or studying" scored 3 The DLQI is calculated by adding the score of each question. The maximum score is 30 and the minimum is 0. The higher the score, the more quality of life is impaired.
Meaning of DLQI Scores 0-1 = no effect at all on patient's life 2-5 = small effect on patient's life 6-10 = moderate effect on patient's life 11-20 = very large effect on patient's life 21-30 = extremely large effect on patient's life
6 months
Primary Change in Severity of Alopecia Tool (SALT) from baseline Change in Severity of Alopecia Tool (SALT) from baseline.
SALT scoring - This calculation is based on a scoring system. The scalp is divided into the following 4 areas:
Vertex: 40% (0.4) of scalp surface area. Right profile of scalp: 18% (0.18) of scalp surface area. Left profile of scalp: 18% (0.18) of scalp surface area. Posterior aspect of scalp: 24% (0.24) of scalp surface area. Percentage of hair loss in any of these areas is the percentage hair loss multiplied by percent surface area of the scalp in that area.
SALT score is the sum of percentage of hair loss in all the above-mentioned areas. For e.g., if the percentage hair loss in vertex, right profile, left profile and posterior aspect is 20, 30, 40 and 50% respecively; then, SALT score = (20 ´ 0.4) = (30 ´ 0.18) + (40 ´ 0.18) + (50 ´ 0.24) = 8+5.4+7.2+12 = 32.6 Lower score denote better outcomes.
6 months
Secondary Change in Hair Count (number of hairs/0.65cm^2) Change in Hair Count (number of hairs/0.65cm^2), as assessed via Trichoscan 6 months
Secondary Change in Hair Density (number of hairs/cm^2) Change in Hair Density (number of hairs/cm^2), as assessed via Trichoscan 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT06110377 - MALE HAIR LOSS - Treatment With Dutasteride Mesotherapy x Dutasteride MMP Technique (Injections With Tattoo Machine) Phase 4
Recruiting NCT05611593 - Study to Evaluate Safety & Usability of a New Formulation for Male Androgenetic Alopecia Phase 1
Completed NCT03676400 - Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia N/A
Recruiting NCT05938569 - Computer-Assisted Hair Restoration Study Using ARTAS System N/A
Not yet recruiting NCT06326359 - Autologous Stromal Vascular Fraction in Treatment of Male Androgenic Alopecia N/A
Recruiting NCT05426629 - Hydraderm for Androgenic Alopecia Phase 4
Recruiting NCT05369481 - Comparison Between Efficacy of Topical Sildenafil 2% and Topical Minoxidil 5% in Treatment of Androgenic Alopecia N/A
Recruiting NCT05827991 - A Clinical Observation of 1565nm Non-ablative Fractional Laser in the Treatment of Androgenic Alopecia N/A
Not yet recruiting NCT06292533 - Effectiveness of Ultrapulse for the Treatment of Androgenic Alopecia Among Malaysian: A Quasi-experimental Study N/A
Completed NCT02824380 - Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia Phase 1
Completed NCT06112782 - Keravive by Hydrafacial for Scalp Health and Enhanced Hair Quality N/A
Completed NCT02594046 - The Effect of Allogeneic Human Adipose Derived Stem Cell Component Extract on Androgenic Alopecia N/A
Recruiting NCT05435625 - Fractional Laser Versus Radiofrequency in Androgenetic Alopecia N/A
Completed NCT05450861 - Effect of the Composition From Fish on Promoting Hair Growth N/A
Completed NCT03506503 - Condensed Nanofat Grafting for Treatment of Androgenetic Alopecia N/A
Completed NCT03467412 - To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin Phase 2
Completed NCT01852487 - Effect of Pumpkin Seed Oil on Hair Growth in Men With Androgenetic Alopecia N/A
Active, not recruiting NCT02914587 - Computer-Assisted Hair Implantation Using ARTAS System VS Manual Implantation Technique Hair Restoration Study N/A
Completed NCT04341363 - Follicular Revival in Androgenic Alopecia: Evaluating Use of Micro-needling N/A
Completed NCT04450602 - A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss N/A